Oxford biomedical spin out recruits healthcare chairman to make contactless vital signs monitoring a commercial reality

Oxehealth, the contactless vital signs monitoring company, has appointed Liberata, Healthcare Homes and Harmoni's Allan Wood as chairman.
Oxehealth Ltd, spun out from Oxford University's Institute of Biomedical Engineering, delivers patented software solutions which work in the real world and utilise innovative, clinically validated algorithms. These solutions have the capability to transform the next generation of healthcare and patient monitoring. They uniquely combine three key attributes: complex signal processing to allow accurate contactless monitoring; machine learning to provide personalised models; and clinical validation.
Its patented Oxecam technology developed by world-leading scientist Professor Lionel Tarassenko and backed by IP Group plc, enables a digital camera, tablet or phone to monitor the vital signs of an individual, without the need for any physical contact or expensive proprietary equipment.
Allan's role will be to form key partnerships within both technology and healthcare organisations, as well as work with the investor community to rapidly expand the business into new areas.
"Oxehealth has the capability to transform our partners' propositions, with the next generation of contactless patient monitoring being a great example. There are many well established providers of primary and secondary healthcare services and many suppliers of applications who would benefit from Oxehealth's technology," said Allan Wood, Oxehealth chairman.
Oxehealth believes the fastest method to transform healthcare in the UK, is for new software utilising innovative algorithms to improve the quality and cost of the existing providers' solutions. Such partners already know the needs of patients and clinicians, and understand how Oxehealth's technology can improve their propositions.
"At Harmoni we partnered with the largest GP co-op to achieve scale and impact. At Oxehealth we have the same desire to collaborate rather than compete," said Allan Wood.
"With a predicted £20-£30 billion deficit applying pressure on the NHS, there is an enormous requirement for technology to enable clinical time to be focused on those who are ill, and less on those who are worried but well."
Allan highlights: "Politicians are forever developing new schemes for the NHS but often lack the practical know-how to apply them. Our technology is proven and is designed by clinicians for patients, and our partnering philosophy focuses on using our partners' established reach to achieve rapid utilisation."